Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT05444712Recruiting
Stem cell transplant after best response in some T-cell lymphomas
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
AmiensAges 18–70 - NCT06059521Recruiting
Comparing a mobile vision test to standard eye exams
This trial tests a new way to measure your eyeglass prescription using a mobile device, compared with a traditional method called retinoscopy. It may help you get a quick and accurate vision check without needing special equipment.
Beijing, Beijing MunicipalityAges 10–46 - NCT04758975RecruitingPhase 2
Venetoclax plus rituximab plus ibrutinib for early CLL
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
Milan, MIAges 18–65 - NCT04908228RecruitingPhase 2
Fixed treatment with ibrutinib and obinutuzumab for untreated CLL
This Phase 2 study tests a fixed-length treatment plan using ibrutinib plus obinutuzumab for people with newly diagnosed, active CLL/SLL that needs treatment. It may help control the leukemia/lymphoma by combining a targeted drug with an antibody therapy.
Milan, MIAges 18 years+ - NCT06065852Recruiting
National registry for rare kidney diseases
This study creates a registry to collect health information from people with rare kidney diseases. It aims to improve understanding and future treatments by tracking patient experiences.
Bristol, South WestAges Any age - NCT06076226Recruiting
Donor telomere length and leukemia transplant outcomes
This trial looks at whether the length of telomeres (the protective caps at the ends of chromosomes) in donor blood cells affects recovery for people with acute leukemia who receive a stem cell transplant. It aims to see if a simple donor blood test can predict how well the transplant works.
Hangzhou, ZhejiangAges 5–90 - NCT04558931RecruitingPhase 2
NK cell therapy to help control multiple myeloma after initial treatment
This Phase 2 trial tests using your own immune cells (NK cells) alone or with isatuximab as “maintenance” treatment to help multiple myeloma stay under control after initial therapy. It may help lengthen the time until the disease grows again by boosting your immune response and targeting myeloma cells.
StockholmAges 18 years+ - NCT01257269Recruiting
Study of genetic and blood features in Upshaw-Schulman
This study looks at how genetic changes (ADAMTS13 gene mutations) and blood test results relate to symptoms and treatment needs in Upshaw-Schulman syndrome. It may help doctors better predict disease behavior and personalize care.
Oklahoma City, OklahomaAges Any age - NCT04687956Recruiting
Preventing arm swelling after breast cancer lymph node surgery
This study looks at ways to prevent arm swelling (lymphedema) related to breast cancer after surgery to remove lymph nodes. It may help people who are getting axillary lymph node dissection lower the chance of long-term swelling.
SeoulAges 19 years+ - NCT06082934RecruitingPhase 1/Phase 2
Triple drug combo for newly diagnosed Ph+ ALL
This trial tests a combination of three targeted drugs (olverembatinib, venetoclax, and dexamethasone) for people newly diagnosed with a specific type of leukemia called Ph+ ALL. The goal is to see if this combination can help control the disease without needing traditional chemotherapy.
Xi'an, ShannxiAges 18 years+ - NCT06081478RecruitingPhase 2
Targeted CAR-T cell therapy for advanced lymphoma or leukemia
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
Beijing, Beijing MunicipalityAges 14–85 - NCT06084962RecruitingPhase 1
GPRC5D-targeted CAR-T cells for advanced multiple myeloma
This trial tests a new type of CAR-T cell therapy that targets a protein called GPRC5D on multiple myeloma cells. It is for people whose myeloma has not responded to or has returned after at least three prior treatments, and aims to see if this targeted approach can help control the disease.
Hangzhou, ZhejiangAges 18–75 - NCT04349358Recruiting
PET/CT scan test to find bone lesions in new myeloma
This trial compares two types of PET/CT scans to see which one better finds lesions (areas of disease) in people with newly diagnosed multiple myeloma. If you qualify, you may help doctors choose the most useful scan to guide care.
BesançonAges 18–75 - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05230680RecruitingPhase 1/Phase 2
Azacitidine with CHOP for newly diagnosed TFH nodal T-cell lymphoma
This trial studies azacitidine plus standard CHOP chemotherapy for newly diagnosed nodal T-cell lymphoma that has a specific “TFH” subtype. It aims to improve treatment control for people with this lymphoma type by testing a new combination in an early-phase study.
SeoulAges 20–85 - NCT05573802RecruitingPhase 1/Phase 2
Belantamab and other medicines for new multiple myeloma
This early-phase study tests how safe and effective belantamab mafodotin is when combined with lenalidomide and dexamethasone, plus a medicine called nirogacestat, in people with newly diagnosed multiple myeloma who cannot have stem cell transplant. It may help shrink the cancer and improve outcomes, while doctors track side effects.
AthensAges 18 years+ - NCT06066905Recruiting
Study of chidamide and azacitidine for AML patients with MRD after transplant
This trial tests whether a combination of two drugs, chidamide and azacitidine (AZA), can help people with acute myeloid leukemia (AML) who still have small amounts of leukemia cells (called MRD) after a stem cell transplant. The goal is to see if this treatment can clear those leftover cells and lower the chance of the leukemia coming back.
Guangzhou, GuangdongAges 18 years+ - NCT06026436Recruiting
Predicting clot and bleeding risk in kidney disease patients after a heart attack
This trial tests whether a blood test looking at platelets and tiny cell particles can help predict future blood clots or bleeding in people who have both chronic kidney disease and a recent heart attack. The goal is to improve treatment safety.
MarseilleAges 18–90 - NCT05328258RecruitingPhase 3
Triptorelin to help protect fertility during cancer chemotherapy
This Phase 3 study tests whether a hormone medicine called triptorelin (a GnRH “fertility-protecting” medicine) can better protect ovarian function while you receive chemotherapy. The goal is to help preserve fertility and reduce the risk of early ovarian failure from cancer treatment.
GothenburgAges 14–42 - NCT03916302Recruiting
Pulmonary embolism registry study in Warsaw
This study keeps a registry (record) of people with a confirmed pulmonary embolism. Your information helps doctors better understand the condition and improve care.
WarsawAges 18 years+ - NCT06105242Recruiting
Sex differences in CTEPH heart function and recovery
This study looks at how CTEPH (a type of high blood pressure in the lungs caused by blood clots) affects heart function differently in men and women. It uses heart ultrasounds and pressure measurements to see if recovery after surgery differs by sex.
Murray, UtahAges 18 years+ - NCT06132711RecruitingPhase 1/Phase 2
CAR-T therapy for relapsed multiple myeloma
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
Xuzhou, JiangsuAges 18–70 - NCT05849857RecruitingPhase 2
Mosunetuzumab for follicular lymphoma that came back quickly
This Phase 2 study tests mosunetuzumab, an antibody treatment, for people with follicular lymphoma that relapsed (came back) or progressed soon after first treatment. It may help shrink the cancer again after early relapse or lack of response to standard therapy.
HelsinkiAges 18 years+ - NCT03110822RecruitingPhase 1
Ruxolitinib, steroids, and lenalidomide for hard-to-treat myeloma
This Phase 1 trial tests a combination of ruxolitinib plus steroids and lenalidomide in people with relapsed or refractory multiple myeloma. It’s designed for patients who have had at least two prior treatment options and whose myeloma is getting worse or not responding.
Alhambra, CaliforniaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.